rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CMPX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Compass Therapeutics at Stifel 2026 Healthcare Conference 2026: FDA path in focus
      Nov 11Investing.comCMPXSF
      Compass Therapeutics at Guggenheim conference: tovecimig faces FDA test
      Nov 9Investing.comCMPX
      Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
      Nov 9Yahoo FinanceCMPX
      Compass Therapeutics presents data on CTX-10726 mechanism
      Nov 6Investing.comCMPX
      Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
      Nov 6Yahoo FinanceCMPX
      Thomas J. Schuetz, MD, PhD, CEO and Co-Founder of Compass Therapeutics, joins JBMS at ESMO 2026
      Nov 2Los Angeles TimesCMPX
      Compass Therapeutics to Participate in Upcoming November Investor Events
      Nov 2Yahoo FinanceCMPX
      Analysts Are Bullish on These Healthcare Stocks: Context Therapeutics (CNTX), Compass Therapeutics (CMPX)

      Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailCMPXCNTX
      Compass Therapeutics publishes tovecimig trial results in JCO
      Oct 24Investing.comCMPX
      Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
      Oct 24Yahoo FinanceCMPX
      Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consists of non-qualified stock options to purch

      Oct 14Yahoo FinanceCMPX
      Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns
      Oct 14Yahoo FinanceCMPX
      Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares
      Oct 2Investing.comCMPX
      Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares
      Sep 25Investing.comCMPX
      Compass Therapeutics Shares Drop After Downgrade From Wedbush
      Sep 23Yahoo FinanceCMPX
      Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ)

      Compass Therapeutics (CMPX) stock slides as Wedbush downgrades the company on FDA call for a new study for lead asset tovecimig. Read more here.

      Sep 23Seeking AlphaCMPX
      Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX)
      Sep 23Seeking AlphaCMPX
      Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’

      Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.

      Sep 23Yahoo FinanceCMPX
      This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Autoliv (NYSE:ALV)

      Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.

      Sep 23BenzingaCMPXALV
      H.C. Wainwright cuts Compass Therapeutics stock price target on FDA trial recommendation
      Sep 23Investing.comCMPX
      Cantor Fitzgerald reiterates Compass Therapeutics stock rating
      Sep 23Investing.comCMPX
      Guggenheim cuts Compass Therapeutics stock price target on FDA trial requirement
      Sep 23Investing.comCMPX
      Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5

      Compass Therapeutics (CMPX) has an average rating of buy and mean price target of $6.75, according t

      Sep 23Yahoo FinanceCMPX
      Citizens cuts Compass Therapeutics stock price target on FDA trial request
      Sep 23Investing.comCMPX
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Tipranks Press Release.

      Sep 23The Globe and MailCMPX
      Compass Therapeutics Faces FDA Pushback on Tovecimig Trial

      Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailCMPX
      Compass Therapeutics (CMPX) was downgraded to a Hold Rating at LifeSci Capital

      Tipranks Press Release.

      Sep 23The Globe and MailCMPX
      Wedbush downgrades Compass Therapeutics stock rating on FDA trial concerns
      Sep 22Investing.comCMPX
      Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug

      Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off tape. Read Also: Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care CMPX Stock Drops After FDA Feedback On Tovecimig BLA Path Compass said the FDA recommended the company run a t

      Sep 22Yahoo FinanceCMPX
      Why Did Compass Therapeutics Stock Plunge Today? - Compass Therapeutics (NASDAQ:CMPX)

      Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig’s FDA marketing application.

      Sep 22BenzingaCMPX
      12 Health Care Stocks Moving In Tuesday's Intraday Session - Jaguar Health (NASDAQ:JAGX), Greenland Mines

      Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by

      Sep 22BenzingaCMPXJAGX
      Compass Therapeutics stock price target maintained at $6 by Stifel
      Sep 22Investing.comCMPXSF
      Compass Therapeutics drops as FDA seeks additional trial for lead asset
      Sep 22Seeking AlphaCMPX
      Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

      The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC.Compass intends to further engage with the FDA as we continue to prepare a BLA submission for tovecimig. Compass remains confident in tovecimig based on the positive results from COMP

      Sep 22Yahoo FinanceCMPX
      FDA requests additional survival trial for Compass’ tovecimig
      Sep 22Investing.comCMPX
      CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing
      Sep 22Yahoo FinanceCMPX

      This is the newest page. Registered accounts read further back.